Holen Sie sich die Stockscreener-App
20.47
0.84%
0.17
Handel nachbörslich:
20.47
Schlusskurs vom Vortag:
$20.30
Offen:
$20.11
24-Stunden-Volumen:
402.43K
Relative Volume:
0.81
Marktkapitalisierung:
$1.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.83
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
+6.67%
1M Leistung:
+0.99%
6M Leistung:
+4.01%
1J Leistung:
-19.85%
1-Tages-Spanne:
$19.97
$20.90
1-Wochen-Bereich:
$18.28
$20.90
52-Wochen-Spanne:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.47 | 1.20B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Chart based exit strategy for Enliven Therapeutics Inc.Quarterly Profit Summary & Consistent Growth Equity Picks - newser.com
Long term hold vs stop loss in Enliven Therapeutics Inc.Quarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Is now a turning point for Enliven Therapeutics Inc.Insider Buying & Stepwise Trade Signal Guides - newser.com
Top chart patterns to watch in Enliven Therapeutics Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com
Will Enliven Therapeutics Inc. stock recover after recent dropWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com
Will Enliven Therapeutics Inc. rebound enough to break even2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com
Why retail investors favor Enliven Therapeutics Inc. stockInsider Selling & Free Daily Entry Point Trade Alerts - newser.com
Developing predictive dashboards with Enliven Therapeutics Inc. dataJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
What analysts say about Enliven Therapeutics Inc stockGlobal Market Influence & Investment Case Studies - earlytimes.in
How to manage a losing position in Enliven Therapeutics Inc.2025 Valuation Update & Precise Buy Zone Identification - newser.com
Head-To-Head Analysis: Enliven Therapeutics (NASDAQ:ELVN) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World
Enliven Therapeutics Inc Stock Analysis and ForecastFundamental Strength Indicators & Low Risk Wealth Building - Early Times
Enliven Therapeutics (NASDAQ:ELVN) Trading 7.2% HigherTime to Buy? - MarketBeat
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 2,800 Shares of Stock - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 1,500 Shares - MarketBeat
Enliven Therapeutics CSO sells $30,045 in shares By Investing.com - Investing.com Canada
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Enliven Therapeutics CSO sells shares worth $135,697 - Investing.com India
Enliven Therapeutics CSO sells shares worth $135,697 By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,000 Shares - MarketBeat
Samuel Kintz Sells 5,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 1,000 Shares of Stock - MarketBeat
Enliven Therapeutics, Inc. $ELVN Shares Purchased by Goldman Sachs Group Inc. - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% HigherWhat's Next? - MarketBeat
Published on: 2025-09-22 00:22:41 - newser.com
Rhumbline Advisers Acquires 2,466 Shares of Enliven Therapeutics, Inc. $ELVN - Defense World
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):